By Anna Rose Welch, editor, Biosimilar Development
In this final installment of the “Biosimilar Editorial Board 2020 Outlook” series, it's clear there is a growing urgency and passion for seeing this industry succeed — and that passion is not to be underestimated.
BPCIA litigants and district courts grappled with new issues in 2019. The Federal Circuit has also been busy, with numerous BPCIA issues pending and a handful of new decisions issued this year. In Part 1 of this article series, we briefly summarize overall statistics regarding BPCIA district court litigation and review ongoing BPCIA district court cases.
For years now, we have witnessed several debates on how biosimilars could potentially lower drug costs, and this proposed legislation is another example of the potential promise that biosimilars have in helping policymakers lower drug costs. But will this bill help?
The bioindustry's most in-depth, global benchmarking and analysis study: Your input is important as we benchmark current global and regional trends affecting the bioindustry. This survey takes 15 to 25 minutes, depending on your areas of expertise. Click here.
When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection, they are able to communicate what is unique about their offering to the right audience at the right time.